patent.fyi
Applications  /  US 2026/0355208
United States Patent Application Publication

US 2026/0355208 A1

Published
Nov 12, 2026
Filed
May 1, 2026
Earliest date on the face
May 2, 2025
Classification
A61K 31/5377
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Blocking signaling through SHP2

What ifWhat if an allosteric SHP2 inhibitor occupied the first drug position?
Claim language“Compound A: or a pharmaceutically acceptable salt thereof”

A small molecule binds an allosteric pocket in SHP2 and stabilizes its closed conformation. This reduces signaling from activated receptor tyrosine kinases to RAS and limits upstream input that drives RAS GTP loading.

1.1Blocking signaling through MEK

What ifWhat if an allosteric MEK inhibitor occupied the first drug position?
Claim language“Compound A: or a pharmaceutically acceptable salt thereof”

A small molecule binds an allosteric pocket in MEK1 and MEK2. It reduces phosphorylation of ERK downstream of RAS and RAF, lowering output from the pathway.

1.2Recognizing mutant KRAS peptides

What ifWhat if engineered T cells targeted tumor cells displaying a KRAS G12C peptide?
Claim language“a KRAS G12C inhibitor”

T cells express a receptor that recognizes a KRAS G12C peptide presented by a matching human leukocyte antigen molecule. Recognition triggers release of cytotoxic granules and kills the presenting tumor cell.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Automated or data-driven variant

Automated three agent concentration matrix

Liquid-handling software generates a plate map with four concentration levels for each of the three agents, including zero. A dispenser prepares the resulting 64 combinations in triplicate on a 384-well plate seeded with KRAS G12C tumor cells and uses vehicle to equalize solvent concentration across wells. A plate reader measures an ATP-dependent luminescence signal, and software normalizes each well to the mean vehicle-control signal.

Specific version of a part

Degrading mutant KRAS

A bifunctional molecule recruits an E3 ubiquitin ligase to KRAS G12C. Ubiquitination directs the recruited protein to the proteasome and reduces the cellular pool of mutant KRAS.

Depleting extracellular growth factors

A soluble fusion protein carries extracellular receptor domains that bind ligands such as epidermal growth factor and transforming growth factor alpha. Ligand sequestration reduces ligand-driven activation of cell-surface EGFR.

Covalent inhibition of KRAS G12C

A small molecule occupies the switch II pocket of GDP-bound KRAS G12C and forms a covalent bond with cysteine at position 12. Binding stabilizes the inactive GDP-bound state and reduces signaling through RAF.

Extracellular EGFR blockade by antibody

An intravenously administered monoclonal antibody binds the extracellular ligand-binding region of EGFR. Receptor occupancy blocks ligand binding and reduces ligand-stimulated receptor phosphorylation.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 9,901,578 B2
Published
Feb 27, 2018
Filed
Jul 17, 2013
Class
A61K 31/519
Document BUS 2023/0233568 A1
Published
Jul 27, 2023
Filed
Jun 23, 2021
Class
A61K 31/519
Claim 1
Document A
Document B
1.1administering to the subject (i) Compound A: or a pharmaceutically acceptable salt thereof
Preferably the composition is comprised of a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of an EGFR kinase inhibitor compound and PDX (including pharmaceutically acceptable salts of each component thereof).
A · US 9,901,578 B2 · ¶ 48
1.2(ii) a KRAS G12C inhibitor, and (iii) an EGFR inhibitor.
The present invention, accordingly, provides a method for the treatment of non-small cell lung cancer in a patient in need thereof, comprising administering to a patient either simultaneously or sequentially a therapeutically effective amount of a combination comprising an EGFR Kinase inhibitor and 10-propargyl-10-deazaaminopterin.
A · US 9,901,578 B2 · ¶ 33
The invention describes anti-cancer therapies comprising using a SOS1 inhibitor in combination with a KRAS G12C inhibitor, each as described herein.
B · US 2023/0233568 A1 · abstract

An empty cell means only that no passage was reproduced there.

Statements in these documents
A need still remains in the art for better treatments for NSCLC.
A · US 9,901,578 B2 · ¶ 8
Thus, a highly purified composition containing PDX can be used in accordance with the invention to treat tumors, including both solid tumors and leukemias.
A · US 9,901,578 B2 · ¶ 4
The invention describes anti-cancer therapies comprising using a SOS1 inhibitor in combination with a KRAS G12C inhibitor, each as described herein.
B · US 2023/0233568 A1 · ¶ 1
These published data suggest that selective targeting of individual SOS isoforms (e.g. selective SOS1 targeting) may be adequately tolerated to achieve a therapeutic index between SOS1/Ras family protein driven cancers (or other SOS1/Ras family protein pathologies) and normal cells and tissues.
B · US 2023/0233568 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0355208 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355208/, SHA-256 097da2502a77f3e801e5de3d663aafcb986fa77dd2e2be1c482909ef288dbc72
First published
Permanent addresshttps://patent.fyi/US20260355208/
Content fingerprint (SHA-256)097da2502a77f3e801e5de3d663aafcb986fa77dd2e2be1c482909ef288dbc72
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi